AYDIN, S. Et Al. 2023. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study. Biomolecules and Biomedicine , vol.23, no.6 , 1089-1095.

AYDIN, S., Kavak, E. E., Topcu, A., BAYRAMGİL, A., Akgul, F., Kahraman, S., ... Aykan, M. B.(2023). Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study. Biomolecules and Biomedicine , vol.23, no.6, 1089-1095.

AYDIN, Selda Et Al. "Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study," Biomolecules and Biomedicine , vol.23, no.6, 1089-1095, 2023

AYDIN, Selda Et Al. "Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study." Biomolecules and Biomedicine , vol.23, no.6, pp.1089-1095, 2023

AYDIN, S. Et Al. (2023) . "Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study." Biomolecules and Biomedicine , vol.23, no.6, pp.1089-1095.

@article{article, author={Selda AYDIN Et Al. }, title={Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study}, journal={Biomolecules and Biomedicine}, year=2023, pages={1089-1095} }